Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Attovia Therapeutics, Inc. has announced the pricing of its upsized initial public offering (IPO), which comprises 17,000,000 shares of common stock priced at $17.00 per share. The offering is expected to generate gross proceeds of approximately $289.0 million before deducting underwriting discounts and commissions. The shares are set to begin trading on the Nasdaq Global Market under the ticker symbol "ATTO" on August 5, 2026, with the offering anticipated to close on August 6, 2026, pending customary closing conditions.

Founded in San Carlos, California, Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation biotherapeutics aimed at treating immune-mediated diseases that currently have high unmet medical needs. The company utilizes its proprietary ATTOBODY biparatopic biologics platform, which facilitates the rapid discovery and development of a diverse array of potential product candidates. Attovia's lead programs include therapeutics targeting chronic pruritic diseases and atopic dermatitis, as well as innovative solutions for inflammatory bowel disease.

The IPO is being managed by a consortium of financial institutions, including Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets, serving as joint book-running managers. LifeSci Capital is acting as a passive book-running manager. The underwriters have also been granted a 30-day option to purchase up to an additional 2,550,000 shares at the IPO price, which could further increase the total capital raised.

The biopharmaceutical sector is experiencing significant growth, driven by increasing demand for innovative therapies that address complex medical conditions. Attovia's focus on immune-mediated diseases positions it well within this expanding market, particularly as the healthcare landscape continues to evolve with advancements in biotechnology and personalized medicine. The successful completion of this IPO will provide Attovia with the necessary capital to advance its clinical programs and expand its research efforts.

Looking ahead, the IPO of Attovia Therapeutics could serve as a bellwether for investor sentiment in the biopharmaceutical space, particularly for companies targeting niche therapeutic areas with high unmet needs. As the market continues to recover from recent volatility, successful public offerings like Attovia's may pave the way for other clinical-stage firms to access public capital markets, ultimately fostering innovation and competition in the biopharmaceutical industry.